UnitedHealth Group
UNH
$426.09
+0.64%
UnitedHealth Group is a diversified healthcare company that provides medical insurance to approximately 51 million members globally and operates a vast healthcare services platform through its Optum franchises. As the largest private health insurer in the U.S., it dominates employer-sponsored, self-directed, and government-backed insurance markets while its Optum businesses span pharmacy benefits, outpatient care, and data analytics. The current investor narrative centers on the company's operational recovery from a challenging 2025, driven by better-than-expected Medicare reimbursement rates, improving margins, and growing optimism around AI-driven efficiencies, though an unresolved DOJ investigation and regulatory overhang continue to fuel debate.…
UNH
UnitedHealth Group
$426.09
Related headlines
Investment Opinion: Should I buy UNH Today?
Rating: Hold. UnitedHealth is a high-quality business with a dominant market position and strong cash flows, but the current valuation near historical highs and decelerating revenue growth limit upside potential. The consensus analyst rating is Buy with an average target of $437.81, implying modest 4.6% upside, which does not provide a sufficient margin of safety for aggressive buying.
Supporting evidence: The trailing PE of 24.95x is at a 39% premium to the industry median of ~18x, while the forward PE of 19.9x is more reasonable but still above the sector average. Revenue growth has slowed to 1.96% YoY, though Q1 2026 net margin recovered to 5.6% from near zero. Free cash flow of $19.67B provides a 5.1% FCF yield, which is attractive. The stock has rallied 43.5% over the past year and is near its 52-week high, suggesting much of the good news is priced in.
Risks & Conditions: The biggest risks are the DOJ investigation, potential Medicare rate cuts, and failure to sustain margin improvement. This Hold would upgrade to Buy if the stock pulls back to $350 (forward PE ~16.6x) or if revenue growth re-accelerates above 5%. It would downgrade to Sell if the DOJ investigation leads to material penalties or if operating margins fall below 7%. Overall, UNH is fairly valued relative to its history and peers, with limited upside from current levels.
Sign up to view all
UNH 12-Month Price Forecast
UnitedHealth's outlook over the next 12 months is balanced. The base case of gradual earnings recovery and modest price appreciation to ~$438 is most likely, supported by analyst consensus and improving margins. However, the bull case (25% probability) requires favorable regulatory outcomes and margin expansion, while the bear case (25% probability) hinges on adverse DOJ or Medicare developments. The current valuation leaves little room for error, making the risk-reward neutral. An upgrade to bullish would require evidence of accelerating revenue growth or a significant pullback in price. A downgrade to bearish would follow negative regulatory news or margin deterioration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $437.81 and implied upside of +2.8% versus the current price.
Average Target
$437.81
0 analysts
Implied Upside
+2.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$287 - $492
Analyst target range
UnitedHealth is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean rating 1.67 on a 1-5 scale where 1 is Strong Buy). The average target price is $437.81, implying approximately 4.6% upside from the current price of $418.52. The distribution leans bullish, with 10 recent ratings showing 8 Buy/Overweight and 2 Hold, and no Sell ratings. The consensus reflects confidence in the company's recovery trajectory and market leadership. The target price range spans from a low of $287.00 to a high of $492.00, representing a wide 71% spread between low and high, indicating significant uncertainty about the stock's future. The high target of $492.00 assumes continued margin expansion, successful integration of Optum, and favorable regulatory outcomes, while the low target of $287.00 prices in risks from the DOJ investigation, potential Medicare rate cuts, or a recession. Recent ratings from major firms (TD Cowen, Truist, Keybanc, Wells Fargo, RBC, HSBC, Morgan Stanley, BofA, Leerink, Mizuho) are predominantly positive, with no downgrades in the past month, suggesting analyst sentiment remains constructive despite the wide target spread.
Drowning in data?
Find the real signal!
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a compelling but nuanced investment case. On the bull side, the company's dominant market position, strong free cash flow, and earnings recovery from the 2025 trough provide a solid foundation. The forward PE of 19.9x is reasonable given expected EPS growth, and analyst consensus remains bullish with a 4.6% upside to the average target. However, the bear case highlights valuation near historical highs, decelerating revenue growth, and unresolved regulatory risks. The single most important tension is whether the earnings recovery can sustain the current valuation premium. If EPS growth meets expectations, the stock could re-rate higher; if not, the elevated trailing PE leaves room for significant downside. Currently, the bull case has slightly stronger evidence given the operational momentum, but the risk-reward is balanced, warranting a Hold rating.
Bullish
- Dominant Market Position and Scale: UnitedHealth serves ~51 million members globally and is the largest U.S. private health insurer. Its Optum businesses (pharmacy benefits, outpatient care, data analytics) provide diversification and cross-selling opportunities, with OptumHealth generating $4.58B in Q1 2026 revenue.
- Strong Earnings Recovery Underway: Q1 2026 net income surged to $6.28B (net margin 5.6%) from near-zero in Q4 2025, driven by improved Medicare rates and cost management. Forward PE of 19.9x implies ~25% EPS growth, supported by analyst EPS estimates of $34.39 for the current year.
- Robust Free Cash Flow Generation: TTM free cash flow is $19.67B, providing ample coverage for dividends ($2.64% yield) and share buybacks. Operating cash flow of $8.91B in Q1 2026 easily covered capex of $763M, demonstrating strong internal cash generation.
- Favorable Analyst Consensus and Upside: 26 analysts rate UNH a Buy (mean 1.67 on 1-5 scale) with an average target of $437.81, implying 4.6% upside. No sell ratings and recent upgrades from major firms reflect confidence in the recovery trajectory.
Bearish
- Elevated Valuation Near Historical Highs: Trailing PE of 24.95x is near the top of its 5-year range (10x-28x) and at a 39% premium to the industry median of ~18x. The stock trades at 96.4% of its 52-week high, leaving limited room for multiple expansion.
- Revenue Growth Deceleration: Q1 2026 revenue grew only 1.96% YoY to $111.7B, down from 10.7% growth in Q4 2024. The multi-quarter trend shows a clear slowdown, raising questions about organic growth sustainability as insurance enrollment normalizes.
- Unresolved DOJ Investigation Overhang: The ongoing DOJ investigation creates regulatory uncertainty that could result in fines, operational restrictions, or reputational damage. This overhang is a key reason for the wide analyst target spread ($287-$492).
- Margin Pressure and Earnings Volatility: Operating margin of 8.0% in Q1 2026 is below the 8.3% in Q1 2025, and Q4 2025 saw near-zero net income due to one-time charges. The medical cost ratio remains sensitive to utilization trends and government reimbursement rates.
UNH Technical Analysis
UnitedHealth is in a powerful sustained uptrend, with the stock up 43.5% over the past year and currently trading at 96.4% of its 52-week range ($234.60–$434.30). The price sits near the highs at $418.52, reflecting strong momentum and investor confidence, though the proximity to the 52-week high of $434.30 suggests the stock may be approaching overbought territory. The 1-year relative strength versus SPY is +22.6 percentage points, underscoring significant outperformance. Short-term momentum is accelerating sharply: the 1-month change is +1.8% and the 3-month change is +32.3%, compared to the 1-year change of +43.5%. This indicates that recent gains have been particularly robust, with the 3-month return nearly matching the full-year return, signaling a strong acceleration in buying pressure. The 1-month relative strength of +1.22 versus SPY confirms near-term outperformance, and the stock has rallied over 80% from its 2025 low, suggesting a powerful recovery trend. The 52-week low of $234.60 provides a clear support level, while the 52-week high of $434.30 acts as resistance. A breakout above $434.30 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below $234.60 would indicate a severe reversal. The stock's beta of 0.63 implies it is 37% less volatile than the S&P 500, making it a relatively defensive holding within the healthcare sector, which is consistent with its large-cap, stable business profile.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$235-$462
Price range past year
Annual Return
+47.9%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +0.3% |
| 3m | +31.3% | +4.7% |
| 6m | +28.7% | +7.5% |
| 1y | +47.9% | +18.4% |
| ytd | +26.7% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
Revenue growth has been steady but decelerating: Q1 2026 revenue of $111.7 billion grew only 1.96% year-over-year, compared to Q1 2025's $109.6 billion (2.0% growth) and Q4 2024's $100.8 billion (10.7% growth). The multi-quarter trend shows a clear slowdown from mid-single-digit growth in 2024 to near-flat growth in 2025-2026, driven by normalization in insurance enrollment and pricing. The UnitedHealthcare segment generated $82.99 billion in revenue, while OptumHealth contributed $4.58 billion, highlighting the dominance of the insurance business. The deceleration raises questions about the company's ability to sustain organic growth, though the Optum services segment remains a key growth driver. Profitability has been volatile but is recovering. Q1 2026 net income was $6.28 billion (net margin 5.6%), a sharp recovery from Q4 2025's near-zero net income of $10 million (net margin 0.01%), which was impacted by one-time charges. Gross margin in Q1 2026 was 22.7%, up from 16.3% in Q4 2025 and 21.7% in Q1 2025, indicating improving cost management. Operating margin of 8.0% in Q1 2026 is healthy and above the 0.3% in Q4 2025, but below the 8.3% in Q1 2025, suggesting margins are still below prior-year levels. The company is solidly profitable with a trailing PE of 24.95 and a forward PE of 19.89, reflecting expected earnings growth. The balance sheet is strong but carries moderate leverage. Debt-to-equity is 0.83, and the current ratio is 0.79, indicating adequate liquidity. Free cash flow (TTM) is $19.67 billion, providing ample coverage for dividends and share buybacks. ROE is 12.8%, reflecting efficient capital use. The company generated $8.91 billion in operating cash flow in Q1 2026, easily covering capital expenditures of $763 million, demonstrating strong internal cash generation and financial flexibility.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 24.95x, while the forward PE is 19.89x, implying the market expects earnings growth of roughly 25% over the next year. The gap between trailing and forward PE suggests investors are pricing in a significant earnings recovery, consistent with the rebound from the depressed Q4 2025 results. Compared to the industry average (Medical - Healthcare Plans), UnitedHealth's trailing PE of 24.95x is at a premium to the sector median of approximately 18x (based on available data), representing a 39% premium. This premium is justified by UnitedHealth's dominant market position, diversified business model, and superior profitability (net margin 5.6% vs. industry average ~4%). However, the forward PE of 19.89x is closer to the industry average, suggesting the market expects the premium to narrow as earnings normalize. Historically, UnitedHealth's trailing PE has ranged from roughly 10x to 28x over the past five years. The current 24.95x is near the top of this historical band, indicating that the stock is priced for optimistic expectations. The historical PE was as low as 9.8x in Q1 2026 (due to depressed earnings) and as high as 28.99x in Q4 2021. The current level suggests the market is pricing in a strong recovery, leaving limited room for error. If earnings fail to meet elevated expectations, the stock could de-rate.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UnitedHealth's balance sheet is solid with a debt-to-equity ratio of 0.83 and TTM free cash flow of $19.67B, but the company faces margin pressure. Operating margin in Q1 2026 was 8.0%, down from 8.3% a year earlier, and net income swung from $6.29B in Q1 2025 to near zero in Q4 2025 due to one-time charges. Revenue growth has decelerated sharply to 1.96% YoY, indicating that the company is increasingly reliant on cost management and buybacks to drive EPS growth. The current ratio of 0.79 suggests adequate liquidity, but the reliance on government reimbursement rates introduces earnings volatility.
Market & Competitive Risks: The stock's trailing PE of 24.95x is at a 39% premium to the industry median, making it vulnerable to multiple compression if growth disappoints. With a beta of 0.63, UNH is less correlated to the market, but sector rotation out of healthcare or a recession could still pressure the stock. The unresolved DOJ investigation adds regulatory overhang, and recent news highlights that Berkshire Hathaway's Greg Abel sold shares, signaling caution. Competitive threats from other insurers and healthcare disruptors could erode market share.
Worst-Case Scenario: If the DOJ investigation results in significant fines or operational restrictions, and Medicare reimbursement rates are cut, earnings could miss expectations. In this scenario, the stock could fall to the analyst low target of $287.00, representing a 31.4% decline from the current price of $418.52. This aligns with the 52-week low of $234.60, though that low was driven by a temporary earnings shock. A more realistic worst case is a 20-30% drawdown to the $290-$330 range, consistent with the stock's historical max drawdown of -29.98%.
FAQ
The primary risks are: 1) Regulatory risk from the unresolved DOJ investigation, which could result in fines or operational restrictions; 2) Valuation risk, as the trailing PE of 24.95x is near historical highs and leaves limited margin of safety; 3) Revenue growth deceleration to 1.96% YoY, which could pressure earnings if not offset by cost cuts; and 4) Government policy risk, as Medicare and Medicaid reimbursement rates are subject to political changes. The most severe risk is a negative DOJ outcome, which could drive the stock to the analyst low target of $287, a 31% decline from current levels.
The 12-month outlook is balanced. The base case (50% probability) sees the stock trading around the analyst average target of $437.81, driven by gradual earnings recovery and stable margins. The bull case (25% probability) targets $450-$492, assuming favorable regulatory outcomes and margin expansion. The bear case (25% probability) sees the stock falling to $287-$350 if the DOJ investigation or Medicare rates disappoint. The most likely scenario is the base case, with modest upside from current levels. Key assumptions include revenue growth of 2-3%, operating margins of 8-8.5%, and EPS of $34.39.
UnitedHealth's trailing PE of 24.95x is at a 39% premium to the industry median of ~18x, suggesting it is overvalued relative to peers. However, the forward PE of 19.9x is closer to the industry average, reflecting expected earnings growth of ~25%. Historically, the stock has traded between 10x and 28x trailing PE, so the current level is near the high end. The market is pricing in a strong recovery and continued margin improvement. Given the decelerating revenue growth (1.96% YoY), the valuation appears full, and the stock is fairly valued to slightly overvalued. Investors are paying a premium for quality and defensiveness.
UnitedHealth is a high-quality business with a dominant market position, strong free cash flow ($19.67B TTM), and a solid earnings recovery from the 2025 trough. However, the stock trades at a trailing PE of 24.95x, near the top of its historical range, and offers only 4.6% upside to the average analyst target of $437.81. The risk-reward is balanced, making it a Hold rather than a Buy at current levels. It is a good buy for long-term investors seeking a defensive holding with reliable dividends, but not for those expecting significant near-term capital appreciation. A better entry point would be below $350, where the forward PE would be more attractive.
UnitedHealth is best suited for long-term investment due to its defensive characteristics (beta 0.63), stable dividend yield of 2.64%, and dominant market position. The stock has low volatility and strong free cash flow, making it a core holding for income-oriented portfolios. Short-term trading is less attractive given the limited upside to the analyst target (4.6%) and the risk of a pullback from near 52-week highs. A minimum holding period of 3-5 years is recommended to benefit from earnings growth and dividend compounding. The stock's 43.5% return over the past year demonstrates its long-term compounding potential.
